Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.85 |
| ▸ | PTGDR | Q13258 | 15/20 | 0.85 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.71 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952238 | 0.88 | PTGDR2 (0.82) | PTGDR2PTGDR | |
| SCHEMBL4508681 | 0.85 | PTGDR2 (0.75) | PTGDR2PTGDR | |
| SCHEMBL4501501 | 0.84 | PTGDR2 (0.68) | PTGDR2PTGDR | |
| SCHEMBL29362700 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL29371844 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL6951622 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL4501444 | 0.81 | PTGDR2 (0.86) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL13816372 | 0.79 | PTGDR2 (0.86) | PTGDR2PTGDR | |
| SCHEMBL4504913 | 0.78 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL13816558 | 0.78 | PTGDR2 (0.65) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585511-B1 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | AMGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-8183293-B2 | Phenyl acetic acid derivatives | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090275659-A1 | Phenyl acetic acid derivatives as inflammation modulators | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009085177-A1 | PHENYL ACETIC ACID DERIVATIVES AS INFLAMMATION MODULATORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275659-A1 | Phenyl acetic acid derivatives as inflammation modulators | NFKBIA, HCAR2, NFATC1 | PTGDR2 891/4885PTGDR 772/4885ABCC3 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.